Inhibrx Biosciences, Inc
Clinical trials sponsored by Inhibrx Biosciences, Inc, explained in plain language.
-
New cancer drug trial seeks to boost immune system against tumors
Disease control OngoingThis early-stage trial is testing a new drug called INBRX-106, both by itself and combined with an existing immunotherapy (pembrolizumab), in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see how …
Phase: PHASE1, PHASE2 • Sponsor: Inhibrx Biosciences, Inc • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New Two-Drug attack on tough head and neck cancers enters Late-Stage testing
Disease control OngoingThis study is testing if adding a new drug called INBRX-106 to a standard immunotherapy (pembrolizumab) works better than the standard drug alone for people with advanced head and neck cancer that has spread or returned. It will involve about 410 patients whose cancer expresses a…
Phase: PHASE2, PHASE3 • Sponsor: Inhibrx Biosciences, Inc • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New drug trial targets rare bone cancer with few treatment options
Disease control OngoingThis study is testing an experimental drug called INBRX-109 for people with advanced chondrosarcoma, a rare bone cancer that cannot be removed by surgery or has spread. The main goal is to see if the drug can slow or stop the cancer's growth better than a placebo. Researchers wil…
Phase: PHASE2 • Sponsor: Inhibrx Biosciences, Inc • Aim: Disease control
Last updated Mar 05, 2026 13:59 UTC